As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Novartis is paying $150 million for a closer look at Schrödinger’s catalog of programs. The Big Pharma will work with Schrödinger to advance some of the computing-enabled R&D shop’s discovery programs ...

SAN ANTONIO -- Research presented at the ObesityWeek annual meeting included studies on rationing of prescription medications ...

"China market is one of the most attractive markets for Edwards," said Leo Tam, senior director of the business unit of Transcatheter Aortic Valve Replacement, Edwards Lifesciences China, citing a lot ...

With full confidence in China, where Novartis recorded 17 percent growth last year, one of the fastest among all major ...

Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an ...

Novartis expects to increase its annual sales by least 5% per year in the coming years, CEO Vas Narasimhan said in an ...

Sales of the medicine, Novartis’s top-selling drug, were 1.4% lower than expected ... in immunology, in neuroscience and cardiovascular disease such that we’re not really reliant on the obesity wave,” ...

Credit: Elle Aon/Shutterstock. Novartis has received US Food and Drug Administration (FDA) accelerated approval for Scemblix (asciminib) to treat adults with newly diagnosed Philadelphia ...

Total net sales at Novartis AG grew by 10% to $12.8bn (€ ... The highest-selling medicines of the company, included the cardiac drug Entresto and psoriasis drug Cosentyx which showed 26% and ...

Total net sales at Novartis AG grew by 10% to $12.8bn (€11.9bn ... The highest-selling medicines of the company, included the cardiac drug Entresto and psoriasis drug Cosentyx which showed 26% and 28% ...

On Tuesday, Novartis AG (NYSE:NVS) reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), ...